News

People with type 1 diabetes have a lack of insulin but also glucagon. When glucagon is not released during a drop in blood glucose, it leads to dangerously low blood sugar levels, a condition that ...
We employed the pancreatic clamp technique [11] using somatostatin to block the endogenous secretion from the islets while substituting insulin and/or glucagon levels by infusions designed to ...
People with type 1 diabetes have a lack of insulin but also glucagon. When glucagon is not released during a drop in blood glucose, it leads to dangerously low blood sugar levels, a condition that ...
Islets of Langerhans are heterogeneous cell aggregates containing β-, α-, δ-, and PP cells, which secrete insulin, glucagon, somatostatin (SST), and pancreatic polypeptide, respectively.
Researchers found that blocking somatostatin restores glucagon release in type 1 diabetes, potentially preventing severe hypoglycemia. The study highlights the relationship between pancreatic ...
Findings indicate that excessive somatostatin inhibits glucagon secretion in type 1 diabetes, offering a novel target for hypoglycemia management strategies.
Blood glucose levels are mainly regulated by the opposing actions of insulin and glucagon—insulin lowers blood sugar levels, while glucagon raises it. Glucagon is regulated by the inhibitory effects ...
Glucagon has the opposite effect in the body to insulin, which lowers blood glucose. Both hormones are produced in the pancreas. People with type 1 diabetes have a lack of insulin but also glucagon.
Glucagon Glucagon, a hormone secreted by the pancreas, raises blood glucose levels. Its effect is opposite that of insulin, which lowers blood glucose levels.
Summary Researchers at the University of Gothenburg found that blocking somatostatin restores glucagon release in type 1 diabetes, potentially preventing severe hypoglycemia. The study highlights the ...
Inhibiting the hormone somatostatin may be a new treatment strategy to prevent dangerous blood glucose drops in type 1 diabetes.